Summary
The severity of the peripheral vasopastic condition in 10 patients with Raynaud's phenomenon was investigated using scintigraphy of both hands. 99MTc-pertechnetate was used as a diffusable tracer and scintigrams were recorded with normal hand skin temperature and following immersion of the hands in ice-cold water.
Cold provocation resulted in a marked reduction of the rate of blood inflow and tissue perfusion in affected hands.
The selective peripheral S2-antagonist ketanserin and placebo were administered intra-arterially according to a double-blind cross-over design. As compared to placebo, ketanserin significantly improved the rate of inflow following cold provocation, and it increased tissue perfusion in the hands of the patients to values normally observed in healthy individuals.
The results support the use of ketanserin in the treatment of Raynaud's phenomenon.
Similar content being viewed by others
References
Editorial (1980) Pathophysiology of Raynaud's phenomenon. Br Med J 281: 1027–1028
Seibold JR (1985) Serotonin and Raynaud's phenomenon. In: Vanhoutte PM (ed) Serotonin and the cardiovascular system. Raven Press, New York
Halpern A, Kuhn PH, Shaftel HE, Samuels SS, Shaftel N, Selman D, Birch HG (1960) Raynaud's disease, Raynaud's phenomenon, and serotonin. Angiology 11: 151–167
Janssen PAJ (1983) 5-HT2-receptor blockade to study serotonin-induced pathology. Trends Pharmacol Sci 4: 198–206
De Cree J, Geukens H, Leempoels J, Verhagen H (1984) Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication. Lancet 2: 775–779
Stranden E, Roald OK, Krohg K (1982) Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin. Br Med J 285: 1069–1071
Roald OK, Seem E (1984) Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders. Br Med J 289: 577–579
Van der Starre PJA, Scheygrond HW, Reneman RS, Kolling JB (1983) The use of ketanserin, a 5-hydroxytryptamine receptor antagonist, for treatment of postoperative hypertension following coronary artery bypass surgery. Anesth Analg 62: 63–69
Wenting GJ, Woittiez AJJ, Man in 't Veld AJ, Schalekamp MADH (1984) 5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 6: 100–109
Gerritsen HA, Kazem I, Hasman A, Kuypers PJ (1974) A new approach to the evaluation of peripheral vascular disease using the gamma camera. Radiology 112: 115–121
Seibold JR, Jageneau AHM (1984) Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2)-receptor. Arthritis Rheum 27: 139–146
Van de Wal HJCM, Wijn PFF, Van Lier HJJ, Skotnicki SH (1985) Quantitative study of the effects of ketanserin in patients with primary Raynaud's phenomenon. Microcirc Endothelium Lymphatics 2: 657–685
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R 41468, a novel antagonist at 5-HT2-receptors. Life Sci 28: 1015–1022
Hechtman DH, Jageneau A (1985) Inhibition of cold-induced vasoconstriction with ketanserin. Microvasc Res 30: 56–62
Van Nueten JM, Janssen PAJ, De Ridder W, Vanhoutte PM (1982) Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit: Effect of ketanserin (R 41468). Eur J Pharmacol 77: 281–287
Van Nueten JM, De Ridder W, Vanhoutte PM (1984) Ketanserin and vascular contractions in response to cooling. Eur J Pharmacol 99: 329–332
De Clerck F, David JL, Janssen PAJ (1982) Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R41468), a selective 5-HT2-receptor antagonist. Agents Actions 12: 388–397
Nielsen SL, Vitting K, Rasmussen K (1983) Prazosin treatment of primary Raynaud's phenomenon. Eur J Clin Pharmacol 24: 424–423
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kunnen, J.J., Dahler, H.P., Doorenspleet, J.G. et al. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy. Eur J Clin Pharmacol 34, 267–271 (1988). https://doi.org/10.1007/BF00540954
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00540954